Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4

Cardiovascular Research

Volumn 104, Issue 3, 2014, Pages 423-431

  Hamdani, Nazha ^a,b   Hervent, Anne Sophie ^c   Vandekerckhove, Leni ^c   Matheeussen, Veerle ^c   Demolder, Marc ^c   Baerts, Lesley ^c   De Meester, Ingrid ^c   Linke, Wolfgang A ^b   Paulus, Walter J ^a   De Keulenaer, Gilles W ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Diabetes; Haemodynamics; Heart failure

Indexed keywords

CYCLIC GMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL PEPTIDASE IV; SITAGLIPTIN; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART STROKE VOLUME; IN VITRO STUDY; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MOUSE; MYOCARDIAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OB/OB MOUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; COMPLIANCE (PHYSICAL); DIABETES MELLITUS, EXPERIMENTAL; DIASTOLE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; HEART; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; MALE; METABOLISM; RANDOMIZATION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; COMPLIANCE; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DIABETES MELLITUS, EXPERIMENTAL; DIASTOLE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG EVALUATION, PRECLINICAL; HEART; HEART VENTRICLES; MALE; MICE; MYOCYTES, CARDIAC; PYRAZINES; RANDOM ALLOCATION; TRIAZOLES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84927933303     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu223     Document Type: Article

References (47)

1. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004;25:543-567.
2. Marwick TH. Diabetic heart disease. Heart 2006;92:296-300.
3. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy the search for a unifying hypothesis. Circ Res 2006;98:596-605.
4. Barouch LA, Gao D, Chen L, Miller KL, Xu W, Phan AC, Kittleson MM, Minhas KM, Berkowitz DE, Wei C. Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity. Circ Res 2006;98:119-124.
5. Brownlee M. The pathobiology of diabetic complications a unifying mechanism. Diabetes 2005;54:1615-1625.
6. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Cir Res 2010;107: 1058-1070.
7. Lacombe VA, Viatchenko-Karpinski S, Terentyev D, Sridhar A, Emani S, Bonagura JD, Feldman DS, Györke S, Carnes CA. Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes. Am J Physiol Regul Integr Comp Physiol 2007; 293:R1787-R1797.
8. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I general concepts. Circulation 2002;105:1727-1733.
9. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II potential mechanisms. Circulation 2002;105:1861-1870.
10. Schannwell C, Schneppenheim M, Perings S, PlehnG, Strauer B. Left ventriculardiastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 2002;98:33-39.
11. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M. Diastolic stiffness of the failing diabetic heart. Circulation 2008;117:43-51.
12. Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006;47:693-700.
13. Cox ME, Rowell J, Corsino L, Green JB. Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug Healtc Pat Saf 2010;2:7-19.
14. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705.
15. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes preclinical biology and mechanisms of action. Diabetes Care 2007;30:1335-1343.
16. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996;137:2968-2978.
17. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. Glp-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013;19:567-575.
18. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24.
19. Matheeussen V, Baerts L, De Meyer G, De Keulenaer G, Van der Veken P, Augustyns K, Dubois V, Scharpé S, De Meester I. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem 2011;392: 189-198.
20. Christopherson KW II, Hangoc G, Broxmeyer HE. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCl12/stromal cell-derived factor-1a-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol 2002;169:7000-7008.
21. Brandt I, Lambeir A-M, Ketelslegers J-M, Vanderheyden M, Scharpé S, De Meester I. Dipeptidyl-peptidase IV converts intactB-type natriuretic peptide into its des-SerPro form. Clin Chem 2006;52:82-87.
22. YuDMT, YaoT-W, Chowdhury S, Nadvi NA, Osborne B, ChurchWB, McCaughanGW, Gorrell MD. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 2010; 277:1126-1144.
23. Sauvé M, Ban K, Momen MA, Zhou Y-Q, Henkelman RM, Husain M, Drucker DJ. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010;59:1063-1073.
24. Khan FZ, Heck PM, Hoole SP, Dutka DP. Dpp-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease clinical perspective. Circ Cardiovasc Imaging 2010; 3:195-201.
25. Huisamen B, Genis A, Marais E, Lochner A. Pre-treatment with a dpp-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther 2011;25:13-20.
26. Gomez N, Touihri K, Matheeussen V, Da Costa AM, Mahmoudabady M, Mathieu M, Baerts L, Peace A, Lybaert P, Scharpé S. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail 2012;14:14-21.
27. Shigeta T, Aoyama M, Bando YK, Monji A, Mitsui T, Takatsu M, Cheng X-W, Okumura T, Hirashiki A, Nagata K. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and-independent actions clinical perspective. Circulation 2012;126:1838-1851.
28. Matheeussen V, Lambeir AM, Jungraithmayr W, Gomez N, Mc Entee K, Van der Veken P, Scharpé S, De Meester I. Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors. Clin Chim Acta 2012;413:456-462.
29. Hamdani N, Krysiak J, Kreusser MM, Neef S, Dos Remedios CG, Maier LS, Krüger M, Backs J, LinkeWA. Crucial role for Ca2(+)/calmodulin-dependent protein kinase-II in regulating diastolic stress of normal and failing hearts via titin phosphorylation. Circ Res 2013;112:664-674.
30. van Heerebeek L, Hamdani N, Falcão-Pires I, Leite-Moreira AF, Begieneman MP, Bronzwaer JG, van der Velden J, Stienen GJ, Laarman GJ, Somsen A. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 2012;126:830-839.
31. Krüger M, Kö tter S, Grützner A, Lang P, Andresen C, Redfield MM, Butt E, dos Remedios CG, LinkeWA. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 2009;104:87-94.
32. Takimoto E, Champion HC, Li M, Belardi D, RenS, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214-222.
33. Bishu K, Hamdani N, Mohammed SF, Kruger M, Ohtani T, Ogut O, Brozovich FV, Burnett JC, Linke WA, Redfield MM. Sildenafil and b-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation 2011;124: 2882-2891.
34. Borbély A, Falcao-Pires I, van Heerebeek L, Hamdani N, Édes I, Gavina C, Leite-Moreira AF, Bronzwaer JG, Papp Z, van der Velden J. Hypophosphorylation of the stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res 2009;104:780-786.
35. Falcão-Pires I, Hamdani N, Borbély A, Gavina C, Schalkwijk CG, van der Velden J, van Heerebeek L, Stienen GJ, NiessenHW, Leite-MoreiraAF. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation 2011;124:1151-1159.
36. Zhang M, Kass DA. Phosphodiesterases and cardiac cGMP: evolving roles and controversies. Trends Pharmacol Sci 2011;32:360-365.
37. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013;309:1268-1277.
38. Flatt PR, Bailey CJ, Green BD. Dipeptidyl peptidase IV (dpp IV) and related molecules in type 2 diabetes. Front Biosci 2008;13:3648-3660.
39. Ahmad S, Wang L, Ward PE. Dipeptidyl (amino) peptidase IV and aminopeptidase M metabolize circulating substance P in vivo. J Pharmacol Exp Ther 1992;260:1257-1261.
40. Aasum E, Hafstad AD, Severson DL, Larsen TS. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 2003; 52:434-441.
41. Semeniuk LM, Kryski AJ, Severson DL. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. AmJ Physiol Heart Circ Physiol 2002; 283:H976-H982.
42. Huynh K, Kiriazis H, Du XJ, Love JE, Jandeleit-Dahm KA, Forbes JM, McMullen JR, Ritchie RH. Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. Diabetologia 2012;55:1544-1553.
43. Chung CS, Hutchinson KR, Methawasin M, Saripalli C, Smith JE, Hidalgo CG, Luo X, Labeit S, Guo C, Granzier HL. Shortening of titin's elastic tandem Ig segment leads to diastolic dysfunction. Circulation 2013;128:19-28.
44. Hamdani N, Paulus WJ. Myocardial titin and collagen in cardiac diastolic dysfunction: partners in crime! Circulation 2013;128:5-8.
45. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263-271.
46. Lenski M, Kazakov A, Marx N, Böhm M, Laufs U. Effects of dpp-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol 2011;51:906-918.
47. Aroor AR, Sowers JR, Bender SB, Nistala R, Garro M, Mugerfeld I, Hayden MR, Johnson MS, Salam M, Whaley-Connell A, Demarco VG. Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulinresistant male Zucker obese rats. Endocrinology 2013;154:2501-2513.